Kornimate/medical-research-clean huggingface dataset:
effect of non-surgical periodontal treatment on oxidative stress and antioxidant status in osas

Conditions: Periodontitis; Obstructive Sleep Apnea; OSAS

Summary: the main objective of this study is to compare the effect of the non-surgical periodontal treatment on serum and saliva oxidative stress parameters in patients with periodontitis and obstructive sleep apnea syndrome (osas) and in patients with periodontitis only.

there is evidence supporting that osas is an independent risk factor for cardiovascular and cerebrovascular diseases such as hypertension, congestive heart failure, myocardial infarction, cardiac-arrhythmia, and stroke.gender, age, smoking, obesity and diabetes, which are risk factors for periodontitis,it is also common in osas at the same time.in addition to common risk factors, both osas and periodontitis have been shown to be associated with increased oxidative stress markers. the investigators aimed to investigate whether non-surgical periodontal treatment on serum and saliva oxidative stress parameters in patients with periodontitis and obstructive sleep apnea syndrome (osas) and in patients with periodontitis only.

Eligibility criteria:
inclusion criteria: * aged ≥18 years old * having more than 16 teeth * bmi\>25 kg/m2 exclusion criteria: * patients with a history of diabetes mellitus or respiratory diseases * patients who were under any medication that was known to influence periodontal tissues * patients with a history of any periodontal treatment in the past 6 months * patients with hormonal changes such as pregnancy or lactation; and 5) patients having fixed dentures or removable prothesis * osas treatment started (using osas therapy device or undergoing surgical operation)

Keywords: osas obstructive sleep apnea periodontitis
visual outcome in patients with symptomatic macular polypoidal choroidal vasculopathy (pcv) treated with either ranibizumab as monotherapy or combined with verteporfin photodynamic therapy (vpdt)

Conditions: Age-related Macular Degeneration; Polypoidal Choroidal Vasculopathy

Summary: this study compared the effect of ranibizumab administered as monotherapy versus ranibizumab administered in combination with verteporfin photodynamic therapy (pdt) on visual acuity in patients with symptomatic macular polypoidal choroidal vasculopathy (pcv). the results of this study provided long-term safety and efficacy data used to generate further guidance on the management of patients with pcv.

patients were randomized to the study in 2 treatment groups: ranibizumab + vpdt combination therapy, and ranibizumab monotherapy. based on the results of the primary analysis at month 12, patients still in the ranibizumab monotherapy group at the time of the switch cut-off time point were switched to the ranibizumab + vpdt combination therapy group until study exit. a total of 168 and 154 patients were included in the ranibizumab + vpdt combined therapy and ranibizumab monotherapy groups, respectively for the fas (month 12 analysis). however, the safety set included 172 and 149 patients, respectively. four patients in the combination therapy group never took vpdt . among them, 1 patient actually received verteporfin injection but no laser injection. thus a total of 3 patients (4-1) in the combination therapy group did not take the actual full vpdt treatment. additionally, 7 patients in the monotherapy group received vpdt and 1 patient from the monotherapy group did not receive ranibizumab treatment. considering the above numbers, safety set included 172 patients (i.e., 168-3+7) in the ranibizumab + vpdt combination therapy group and 149 patients (i.e., 154-7+3-1) in the ranibizumab monotherapy group for month 12 analysis. for the month 24 safety analysis, the 14 patients in the ranibizumab monotherapy group who were switched to ranibizumab +vpdt combination therapy group were analyzed as a separate group, ie, ranibizumab 0.5 mg + vpdt (switched). .

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of symptomatic macular pcv in the study eye * a qualifying vision score at study entry * a qualifying lesion size in the study eye at study entry exclusion criteria: * active inflammation or infection in the study eye * uncontrolled intraocular pressure in the stuy eye * ocular condition in the study eye which may impact vision and confound study outcomes * prior treatment of the study eye with anti-vegf therapy, verteporfin pdt, other laser and surgical interventions, intraocular corticosteroids

Keywords: polypoidal choroidal vasculopathy visual acuity ranibizumab verteporfin pdt
post-market study of the tripod-fix vertebral body augmentation system in osteoporotic vertebral compression fractures

Conditions: Osteoporotic Vertebral Compression Fractures

Summary: the objective of this post-market clinical follow-up study is to evaluate the safety and performance of the tripod-fix in the treatment of vertebral compression fractures (vcf) resulting from osteoporosis.

this study is a prospective, multicenter, open-label, single-arm, pmcf study. the sample size for this study will be 50 patients. eligible patients will be treated with tripod-fix on day 0 and will be followed for a total of 12 months.

Eligibility criteria:
inclusion criteria: 1. provision of signed and dated informed consent form prior to any study procedures 2. stated willingness to comply with all study procedures and availability for the duration of the study 3. skeletally mature males and females 4. 1 painful vcf which meets all of the following criteria: 1. fracture due to diagnosed or presumed underlying osteoporosis (t-score \< -2.5 points) 2. vcf between t6 and l5 3. vcf shows loss of height in the anterior, mid or posterior third of the vertebral body from an estimated pre-fracture configuration, but no more than 50% based on x-ray, ct or mri at baseline. 4. the index fracture is acute or persistent (not healed), as demonstrated by mri (or bone scan if the patient is contraindicated for mri). 5. investigator believes target vertebral body is suitable for tripod-fix procedure (e.g., appropriate pedicle diameter) assessed on radiography preoperative. exclusion criteria: tripod-fix is not indicated for any other application other than that for which it is designed. contraindications for tripod-fix include, but are not limited to: . 1. patient presenting a loss of vertebral height \>50% compared to estimated pre-fracture height 2. sclerotic fracture 3. patient with a prior history of intolerance or of allergic reaction to titanium and/or one of the components of the pmma cement 4. patient suffering from irreversible coagulopathy or undergoing anticoagulant treatment at the moment of surgery or at least 8 days prior to inclusion 5. active infection (systemic or in the target vertebra) 6. patient suffering from a severe or uncontrolled systemic disease 7. patient presenting a pathological fracture with the presence of a mass within the spinal canal 8. patient presenting neurological damage caused by vertebral fracture 9. patient pregnant or likely to be so or breastfeeding 10. patient vertebral anatomy not compatible with the size of the implant or instrumentation 11. fracture geometry making the insertion of the implant impossible
hbot in the treatment and prevention of agvhd

Conditions: Hyperbaric Oxygen Therapy; Acute-graft-versus-host Disease

Summary: allogeneic hematopoietic stem cell transplantation (allo-hsct) is a potentially curative therapeutic strategy for patients with hematopoietic malignancies. however, the therapeutic benefits and wider application of allo-hsct are limited by acute graft-versus-host disease (agvhd), the latter remains a major obstacle against long-term survival for this population. new agvhd prophylactic and therapeutic strategies that are superior in efficacy, safety, cost-effectiveness, and less technically demanding are still in desperate need. hyperbaric oxygen therapy (hbot) has been confirmed as an effective and economical therapeutic modality for hemorrhagic cystitis (hc) whether induced by infection or acute graft-versus-host disease (agvhd) for transplant recipients. however, little is known about its involvement in agvhd. in this study, the investigators designed a randomized, controlled, and open clinical trial to confirm the safety and efficacy of hbot on agvhd in patient underwent allo-hsct.

allogeneic hematopoietic stem cell transplantation (allo-hsct) is a potentially curative therapeutic strategy for patients with hematopoietic malignancies. however, the therapeutic benefits and wider application of allo-hsct are limited by acute graft-versus-host disease (agvhd), the latter remains a major obstacle against long-term survival for this population. new agvhd prophylactic and therapeutic strategies that are superior in efficacy, safety, cost-effectiveness, and less technically demanding are still in desperate need. although a variety of immune and non-immune cells are involved in the development of agvhd, reactive oxygen species (ros) has been proved as the primary triggers of the inflammatory response and play a key role in the pathogenesis of agvhd. therefore, strategies targeting ros production are crucial for effectively managing agvhd. hyperbaric oxygen therapy (hbot) is a well-established treatment method, which is used to improve non-healing ulcers secondary to agvhd and hemorrhagic cystitis (hc) after allo-hsct whether induced by infection or agvhd. even the exact mechanism is not fully understood, hbot was demonstrated to reduce a series of pro-inflammatory cytokines release and can improve the action of antibiotics. in this study, the investigators plan to initiate a randomized, controlled, and open clinical cohort study confirm the safety and efficacy of hbot on agvhd in patient underwent allo-hsct.

Eligibility criteria:
inclusion criteria: * patients undergoing allogeneic stem cell transplantation * patients develop agvhd * the count of neutrophilia cells over 0.5 \* 109/l, hemoglobin over 60 g/l, platelet over 30 \*109/l * signed informed consent exclusion criteria: * unsuitable to the study due to severe complication such as uncontrolled severe infection * claustrophobia * ear diseases such as otitis media * eye diseases such as glaucoma * epilepsy history * important organ dysfunction * coagulopathy
physical and cognitive effects of fluoroscopy

Conditions: Dehydration; Radiation Exposure

Summary: background and objectives: the researchers will perform this study to reveal the clinical meaning of fatigue, headache, diarrhea, and impaired cognitive functions that are often expressed verbally in healthcare professionals who are exposed to fluoroscopy. methods: after obtaining written informed consent, 84 samples will be included in the study. for operating room employees who meet the criteria determined before and after the operation; mini-mental state examination, weight, heart rate, non-invasive blood pressure value, vas score for headache, radiation exposure time on fluoroscopy device, rad measurement with the help of personal dosimeter before and after surgery, and total time in the operating room will be recorded.

background and objectives: nowadays, operations under fluoroscopy are performed at increasing rates with the aim of increasing case management and surgical success. due to this increasing exposure to radiation, it is important to show that fluoroscopy has an impact on employees not only annually but also daily. the researchers will perform this study to reveal the clinical meaning of fatigue, headache, diarrhea, and impaired cognitive functions that are often expressed verbally in healthcare workers who are exposed to fluoroscopy. methods: after obtaining written informed consent; 84 samples consisting of orthopedic surgery and anesthesia residents and orthopedic operating room nurses between the ages of 18-60 who do not have cardiological, neurological and psychiatric diseases, have had fluoroscopic operations lasting more than 2 hours, wear protective scopy gowns and collar during surgery, will be included in the study. the total number of samples required for the study will be reached by taking repeated measurements on consecutive days from the same sample group, but not on the same day. for operating room employees who meet the criteria determined before and after the operation; mini-mental state examination, weight, heart rate, non-invasive blood pressure value, vas score for headache, radiation exposure time on fluoroscopy device, rad measurement with the help of personal dosimeter before and after surgery, and total time in the operating room will be recorded. this prospective study will be executed between december 2020 and june 2021.

Eligibility criteria:
inclusion criteria: 1. volunteering to participate in the study 2. asa classification 1 or 2 3. not leaving the operating room during the operation 4. to be carrying a fluoroscopy gown, protective collar, and dosimeter. exclusion criteria: 1. having a psychiatric illness 2. having a neurological disease 3. being under the age of 18 4. presence of cardiac pathology 5. being pregnant or suspected of pregnancy

Keywords: medical professionals intraoperative fluoroscopy low dose radiation
efficacy and tolerability of nolotil i.v. vs. placebo i.v. in the prevention of postoperative pain in children undergoing minor surgery

Conditions: Pain

Summary: study to assess the analgesic efficacy in the prevention of postoperative pain in children undergoing minor surgery (herniorraphy, tonsillectomy) and to assess the tolerability of metamizol in this group of patients.


Eligibility criteria:
inclusion criteria: * children of either sex between 6 and 11 years of age * patients undergoing routine inguinal hernia repair or tonsillectomy * written informed consents by the guardian, according to the guidelines of good clinical practice and current legislation * the ability of the patient to understand and carry out the visual analogue scale assessments * patients with a physical status american society of anesthesiologist i or ii class exclusion criteria: * the use of any drug with analgesic properties in the 24 hours prior to the administration of the study drug * surgery with a foreseen duration over 60 minutes * patients with a nutritional index of less than 90 or greater than 120 * patients with a body mass index which was not between the 3rd centile and the 97th centile for age * patients with any illness or malformation (except hernia) which, in the doctor's opinion, contraindicated the use of metamizol (aplastic anemia, agranulocytosis of a toxicological etiology, severe renal disease, etc.) * patients who have received in the previous 7 days or need currently anticoagulant treatment * significant allergy or known hypersensitivity to metamizol, its excipients and/or to other nonsteroidal antiinflammatory drugs * patients in whom the anesthetic regimen required by the protocol cannot be used * patients who have participated in another clinical trial in the past four weeks or are currently participating in another clinical trial * patients with any psychological disturbance which, in the investigator's opinion makes the patient unsuitable for inclusion in the trial
biomarkers in tissue samples from patients with stage i or stage iii endometrial cancer

Conditions: Endometrial Cancer

Summary: rationale: studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. purpose: this research study is studying at biomarkers in tissue samples from patients with stage i or stage iii endometrial cancer.

objectives: * to identify microrna expression patterns associated with lymph node metastasis in samples from patients with endometrial cancer. outline: banked tumor tissue specimens are analyzed for microrna expression profiling by microarray analysis and reverse transcriptase-pcr assays.

Eligibility criteria:
disease characteristics: * histologically confirmed endometrioid endometrial cancer * stage ia, ib, ic, or iiic disease * any grade * enrolled and evaluated on gog-0210 molecular staging study of endometrial cancer * consented to allow their specimens and clinical data to be collected and stored for future research * underwent complete surgical staging, including the following: * hysterectomy * bilateral oophorectomy * washings as well as pelvic lymphadenectomy (sampling of four left and four right pelvic lymph nodes) * para-aortic lymphadenectomy (sampling of one left and one right para-aortic lymph node) * sufficient high-quality frozen primary tumor for testing with ≥ 75% tumor cellularity and ≤ 10% necrosis patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: stage i endometrial carcinoma stage iii endometrial carcinoma
multi-component real-time remote rehabilitation in sarcopenia

Conditions: Sarcopenia

Summary: this study is designed as a single center, non blinded, randomized controlled, dual arm trial. we designed to allocate participants in a 1:1 ratio to compare the effects of real-time remote rehabilitation and self rehabilitation with multiple components on muscle strength, muscle mass, balance, and walking ability in patients with sarcopenia. each participant signs an informed consent form before registering for the study. this protocol follows the 2013 standard protocol project: intervention trial recommendation guidelines.

this study is designed as a single center, non blinded, randomized controlled, dual arm trial. we designed to allocate participants in a 1:1 ratio to compare the effects of real-time remote rehabilitation and self rehabilitation with multiple components on muscle strength, muscle mass, balance, and walking ability in patients with sarcopenia. each participant signs an informed consent form before registering for the study. this protocol follows the 2013 standard protocol project: intervention trial recommendation guidelines.

Eligibility criteria:
inclusion criteria: according to the diagnostic criteria for sarcopenia established by the asian working group for sarcopenia (awgs): 1. low muscle strength: handgrip strength \< 28 kg for men, \< 18 kg for women; and/or 2. low physical performance: usual gait speed (6-meter gait speed, 6mgs) ≤ 1.0 m/s; and/or 3. low muscle mass: skeletal muscle mass index (smi) \< 7.0 kg/m² for men, \< 5.7 kg/m² for women. exclusion criteria: 1. unable or unwilling to undergo body composition measurement. 2. regular exercise habits within the past 6 months (resistance training ≥ 2 times/week, moderate-intensity aerobic exercise ≥ 3 times/week). 3. history of unstable cardiovascular disease, stroke, diabetes, psychiatric disorders, or other contraindications to exercise in the past 6 months. 4. previously diagnosed with rheumatoid arthritis. 5. history of conditions affecting motor coordination, such as poliomyelitis sequelae, epilepsy, or stroke sequelae. 6. presence of implanted medical devices due to previous fractures, heart disease, or other conditions. 7. diagnosis of malignant tumors. 8. unable to independently use the wechat mini program used in this study.

Keywords: sarcopenia remote rehabilitation muscle strength real-time remote rehabilitation
medroxyprogesterone acetate vs lng-ius in early-stage endometrioid carcinoma and atypical hyperplasia patients

Conditions: Fertility Sparing

Summary: in modern society, endometrial cancer (ec) and atypical hyperplasia is the most frequent desease which can affect the fertility of young patients. for young patients, there is a growing need to treat tumors and fertility sparing. advaced studies have confirmed thatfertility preservation therapy has better tumor and pregnancy outcomes in specific patients with early gynecological tumors. clinically, evidence-based guidelines are urgently needed to guide the screening and treatment of women who are suitable for fertility preservation. fertility-sparing treatment predominantly involves the use of oral progestins and levonorgestrel-releasing intrauterine devices, which have been shown to be feasible and safe in women with early stage ec and minimal or no myometrial invasion. however, data on the efficacy and safety of conservative management strategies are primarily based on retrospective studies.the present study aims to compared the therapeutic effect of medroxyprogesterone acetate (mpa) and levonorgestrel-releasing intrauterine system (lng-ius) in early-stage endometrioid carcinoma and atypical hyperplasia patients


Eligibility criteria:
inclusion criteria: 1. age ≤ 45 years old; 2. diagnostic curettage pathology is highly differentiated endometrioid adenocarcinoma; 3. pelvic augmentation mri or / and vaginal color ultrasound doppler examination, tumor confined endometrium; 4. no suspicious metastatic lesions; 5. endometrial pathological tissue specimens with strong positive expression of estrogen and progesterone receptors; 6. blood ca125 is normal; 7. no progesterone therapy and contraindications to pregnancy; 8. the patient himself has a strong desire to preserve fertility, and the patient should fully understand that fertility preservation treatment is not the standard treatment method; 9. conditional acceptance of close follow-up. exclusion criteria: 1. type ii endometrial cancer; 2. patients with abnormal liver and kidney function and other contraindications to progesterone therapy; 3. other parts of the body are concurrent or successively complicated by other malignant tumors; 4. the patient and his/her family are unable to sign the informed consent form for any reason; 5. unconditional follow-up.
physical exercise on physiological adaptation capacity and chronic pain in individuals with cardiovascular risk

Conditions: Cardiometabolic Risk Factors

Summary: this research focuses on studying the effects of a 12-week exercise program on the health of individuals at risk of heart disease. the program includes high-intensity interval training (hiit) and muscle endurance resistance exercise (ere). the researchers aim to observe the impact of these exercises on physiological adaptability, physical capacity, cardiovascular risk factors, metabolism, body composition, and chronic pain. the participants will be inactive adults with a body mass index (bmi) between 25 and 39.9, who are enrolled in a cardiovascular health program. individuals with certain serious conditions, such as bone or heart problems, pulmonary diseases, cancer, or those who do not adequately understand instructions or spanish, are ineligible to participate. patients will be selected by the program team and divided into three groups: one will perform hiit, another will engage in ere, and a control group will continue their usual treatment. participants will be assessed at different times: before starting, at 4 weeks, at 8 weeks, and at the end of the program. various health aspects will be measured, including physical activity, quality of life, physical capacity, cardiovascular risk factors, metabolism, body composition, and pain level.


Eligibility criteria:
inclusion criteria: * physically inactive: not engaging in 300 minutes of moderate or 150 minutes of vigorous physical activity per week, measured with the ipaq questionnaire. * bmi between 25 and 39.9 kg/m². * belonging to the cardiovascular health program of external family health center valdivia. * presenting or not presenting chronic non-cancerous pain. exclusion criteria: * bone disease. * ischemic disease or arrhythmia. * chronic obstructive pulmonary disease (copd) or asthma. * uncontrolled chronic diseases. * individuals unable to understand instructions. * individuals who do not speak spanish. * history of previous oncological disease or under investigation for suspected neoplastic disease in any part of the body.

Keywords: exercise high-intensity interval training resistance training interindividual variability intraindividual variability physiological adaptation cardiometabolic risk factors pain chronic pain musculoskeletal pain pain threshold pain perception exercise-induced hypoalgesia metabolic flexibility indirect calorimetry body composition cardiorespiratory fitness muscle strength